Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities’ Unit-III, a Formulation manufacturing facility has received a Warning Letter from United States Food and Drug Administration (USFDA). There is no impact on the existing supplies to the US markets.
In May 2024, USFDA had determined the inspection classification status to Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities’ unit III, formulation manufacturing facility as ‘Official Action Indicated (OAI)’.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
